Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 13/20 | 0.49 |
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4428832 | 0.83 | CDK9 (0.40) | AGPAT2FBP1EGFRERBB2 | |
| SCHEMBL2988060 | 0.81 | CLK4 (0.43) | TSHRHPGDEGFR | |
| SCHEMBL4282695 | 0.80 | AGPAT2 (0.67) | AGPAT2DHFR | |
| SCHEMBL4281823 | 0.79 | AGPAT2 (0.72) | AGPAT2 | |
| SCHEMBL4288289 | 0.78 | AGPAT2 (0.61) | AGPAT2TSHR | |
| SCHEMBL15486181 | 0.74 | EGFR (0.38) | TSHRFBP1EGFRERBB2 | |
| SCHEMBL29475115 | 0.74 | CLK4 (0.39) | AGPAT2TSHRKMT2AHPGDMEN1 | |
| SCHEMBL21175319 | 0.74 | CLK4 (0.39) | AGPAT2TSHRKMT2AHPGDMEN1 | |
| SCHEMBL4280067 | 0.74 | CYP1A2 (0.58) | AGPAT2KMT2AHPGDMEN1EGFR | |
| SCHEMBL4290421 | 0.71 | AGPAT2 (0.54) | AGPAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | CELL THERAPEUTICS, INC. (US) | 2009-04-16 | — | — | US | disclosed |
| US-7419984-B2 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20040204386-A1 | Pyrimidines and uses thereof | CELL THERAPEUTICS, INC. | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204386-A1 | Pyrimidines and uses thereof | LPCAT3, LPCAT1, APRT | AGPAT2 100/4885DHFR 96/4885TSHR 4049/4885 |
| US-20090099183-A1 | PYRIMIDINES AND USES THEREOF | LPCAT3, LPCAT1, APRT | AGPAT2 94/4885DHFR 133/4885TSHR 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.